Directors’ Report Measure and Commentary Threshold 50% Target 100% Maximum 200% Efficiency and Reliable Supply • 27 plasma centres opened taking the global total to 330 • US regulatory clearance received for the new plasmapheresis platformwith rollout to be completed by the end of 2023 • Progress against key milestones on our quality system integration initiative • Record volume of ~135 million doses distributed in our 2022 influenza campaign • Fill and finish capacity expansion projects at our Liverpool and Holly Springs sites completed • Progression of capital expansion projects including the new cell culture influenza vaccine facility in Australia • New safety system live across all locations • Above target delivery against the IG roadmap Digital Transformation • Progression of the converged enterprise network strategy across CSL and Seqirus • Initiation of our next generation Donation Management System initiative • Enhanced CSL Plasma Donor app with new functionality • Significantly enhanced partnership with Capgemini • Milestones achieved in our digital transformation to build capabilities in digital experiences, and insights and analytics 3 Any STI that was not earned was automatically forfeited. 6.2 STI Outcomes by Executive KMP in 2022 The financial performance of CSL (NPAT and CFO) makes up the majority weighting of the KPIs for Executive KMP – 60%, incentivising the delivery of strong financial performance. Achievements that contributed to the outcomes detailed in Table 3 below can be found in Table 2 of this Report. The Board made no adjustments under the Malus and Clawback Policy and no risk management, behaviour or compliance issues involving Executive KMP were identified during the joint consultation between the HRRC and ARMC. Table 3: STI Outcomes in 2022 Executive Value of STI Earned US$ Target STI Opportunity as a % of FR Maximum STI Opportunity as a % of FR STI Earned as % of Target Opportunity STI Earned as % of Maximum Opportunity3 STI Earned as % of FR Financial Performance Outcome Individual Performance Outcome P Perreault 3,029,931 120% 240% 140% 70% 168% Between Target and Maximum Between Target and Maximum J Linton 1,149,742 85% 170% 105% 72% 122% Between Target and Maximum Between Threshold and Target P McKenzie 1,273,770 100% 200% 130% 65% 130% Between Target and Maximum Between Threshold and Target CSL Limited Annual Report 2021/22 82
RkJQdWJsaXNoZXIy MjE2NDg3